Changes in Hong Kong stocks | Nuochengjianhua (09969) rose more than 4% self-developed novel TYK2 inhibitor ICP-332 to treat CSU approved for phase II/III clinical trials

The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose by more than 4%. As of press release, it had risen 3.87% to HK$13.69, with a turnover of HK$37.913,800.

According to news, on December 18, according to Nuochengjian's official WeChat account, the company announced that the novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU) was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to conduct phase II/III clinical trials.

Soficitinib is an efficient and highly selective novel oral TYK2 inhibitor independently developed by Nuochengjianhua. It has been developed to treat various T-cell-related autoimmune diseases. The indications currently being developed cover the broad dermatology market, including atopic dermatitis, vitiligo, pruritus nodular, urticaria, etc. As a member of the JANUS kinase (JAK) family, TYK2 is a key kinase in the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammation. Soficitinib blocks cytokine signaling pathways such as IL-4, IL-13, and IL-31 that drive mast cell activation and inflammatory response, thereby reducing itching and wind formation and improving CSU symptoms.

According to relevant data, there are about 50 million patients with chronic spontaneous urticaria worldwide, and the global CSU market is expected to reach 3 billion US dollars by 2029.